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ABSTRACT
Atopic dermatitis (AD) is a common, chronic or chronically relapsing, multifactorial skin disease that mainly oc-
curs in children but affects also adults. AD usually begins early in life and often concerns people with a personal
or family history of asthma and allergic rhinitis. AD is characterized by eczematous changes in the epidermis
and originates from a late, T-cell mediated reaction associated to the formation and production of memory T-
cell of TH2 type, occurrence of homing receptor at skin level and cutaneous lymphocyte-associated (CLA) anti-
gens. Extrinsic or allergic AD, but not intrinsic AD, shows high total serum IgE levels and the presence of spe-
cific IgE for environmental and food allergens. A pivotal role in the pathogenesis of AD is played by filaggrin, a
protein contained in the granular layer of the epidermis regulating the aggregation of keratin filaments. Mutation
in the filaggrin gene causes decreased barrier function of the corny layers of the epidermis. This favours the en-
ter through the skin of environmental allergens, especially the house dust mite, that further facilitates such en-
tering by the proteolytic activity of its major allergen Der p 1. In fact, recent advances suggest that the dust
mite, more than foods, is the major cause of allergic AD. As far as the causal diagnosis of AD is concerned,
there is notable evidence supporting the capacity of the atopy patch test (APT) to reproduce the pathophysi-
ologic events of AD. This makes APT a valuable diagnostic tool for AD.
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INTRODUCTION
“Everyone knows how eczema looks like, yet no one
knows what eczema is.”
Heinrich Adolf Gottron (1890-1974)
Atopic diseases, including rhinitis, asthma, and
atopic dermatitis are a major health problem world-
wide and their prevalence is particularly high in chil-
dren.1 In 2004, the World Allergy Organization
(WAO) introduced a revised nomenclature for atopy
and atopic diseases, defining atopy only in association
with IgE-sensitization. Hence, the term atopy should
be used in combination with documented specific IgE
antibodies in serum or with a positive skin prick test.2
Thus, the non-IgE-associated (formerly defined as
intrinsic or atopiform dermatitis) form has to be dis-
tinguished from the IgE-associated (formerly defined
as extrinsic) form. Concerning atopic dermatitis
(AD), even if some authors propagate the concept of
2 distinct forms, i.e. atopiform dermatitis versus
atopic dermatitis, the non-IgE associated form may
represent a transitional phase of the IgE-associated
form, at least in infancy.3
AD is a common, chronic or chronically relapsing,
severely pruritic, multifactorial skin disease that
mainly occurs in children.4 AD is characterized by ec-
zematous changes in the epidermidis. It normally be-
gins early in life and often occurs in people with a per-
sonal or family history of asthma and allergic rhini-
tis.5 The lifetime prevalence of AD is estimated to 15-
30% in children and 2-10% in adults, with a mean
prevalence of 17%, while the incidence of AD has in-
creased 2-3 fold during the past 3 decades in industri-
alized countries. The highest prevalence was typically
found in Northern Europe.1 The prevalence of AD in
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rural areas and in non affluent countries is signifi-
cantly lower, emphasizing the importance of life-style
and environment in the mechanisms of atopic dis-
eases, which could be explained by the “hygiene hy-
pothesis”,6 however this is a concept still subject to
debate.7 Theories to explain the rise in AD include a
decrease in the number of children who are exclu-
sively breast-fed, an overall increased awareness of
AD, an increased exposure to air pollution, and an in-
creased exposure to allergens.8,9 Extensive research
has demonstrated that a combination of food allergy,
defects in the gut mucosal barrier, and increased in-
testinal permeability concur to the pathogenesis of
AD.10
In children, the onset of AD occurs in 45% during
the first 6 months of life, in 60% during the first year,
and in 85% before the age of 5.11 Up to 70% of these
children have a spontaneous remission before adoles-
cence. The disease can also start in adults (the so-
called late-onset AD), and in a substantial number of
these patients there is no sign of IgE-mediated sensi-
tization.12
FACTORS UNDERLYING AD
The role of genetic factors in AD is clearly demon-
strated by twin studies: the concordance rate for AD
is higher among monozygotic twins (77%) than
among dizygotic twins (15%).13 The importance of ge-
netic factors in AD is further underlined by the find-
ing that a positive parental history is the strongest
risk factor for AD; the incidence rate is doubled if AD
is present in one parent, and tripled if both parents
are affected.
Whereas, allergic asthma or allergic rhinitis in a
parent appears to be a minor factor in the develop-
ment of AD in the offspring, suggesting AD-specific
genes.14 Genome-wide scans15 have highlighted sev-
eral possible AD-related loci on chromosomes 3q21,16
1q21, 16q, 17q25, 20p17 and 3p26.18 An appealing as-
pect for the researchers involved in AD is the role of
AD in the “allergic march”: recently Burgess et al.
posed the question: “Does eczema lead to asthma?”.19
Interestingly, the phase Ia of the ISAAC study,
showing the clear association among eczema, rhinitis
and asthma, suggested the possible occurrence of the
allergic march.20 In a comprehensive review of AD,
Wüthrich noted a reported high prevalence of AD
(10% to 15%) that had been increasing in recent dec-
ades, a high persistence beyond puberty (40% to
60%), and a high rate of developing allergic rhinitis
andor asthma over time in children with AD (40% to
60%).21
In fact, AD precedes the development of asthma
and allergic rhinitis, suggesting that AD is an “entry
point” for subsequent allergic disease.22 Important
observations were provided by the German Multicen-
ter Atopy Study (MAS), which recruited 1,314 new-
borns of whom 499 were at increased risk of atopic
disease. In terms of early AD (onset before the age of
2 years) and subsequent asthma, only those children
with early AD and concomitant early wheeze (in the
first 3 years of life) were at increased risk of current
wheeze or bronchial hyper-responsiveness (BHR) at
the age of 7 years. In contrast, the majority of chil-
dren with early AD and no early wheeze were not at
increased risk of current wheeze or BHR at that age.
Furthermore, in those children with concomitant AD
and early wheeze, half had AD beginning before or
with wheeze and half began wheezing before AD.
The authors concluded that “rather than early AD be-
ing a risk factor for subsequent asthma in a progres-
sive atopic march, it seems more likely that a certain
phenotype exists as co-expression of asthma and AD
characterized in early life by AD plus either wheezing
or a specific pattern of atopy sensitization.”11
Additionally, the data from the Melbourne Atopic
Cohort Study (MACS) help understand the situation
yet further: MACS recruited before birth 620 infants
born between 1990 and 1994 in Melbourne, Australia,
who had a family history of allergic disease. The
authors found that infants who developed eczema
within the first 6 months of life were at increased risk
of new sensitization,23 a finding later replicated within
another Australian birth cohort.24 Moreover, Lowe et
al.25 found that infants with atopic eczema (eczema
plus sensitization) were at greater risk at ages 6 and 7
years of having childhood asthma (OR 3.52; 95% CI
1.88-6.59), allergic rhinitis (2.91; 1.48-5.71), and both
childhood asthma and allergic rhinitis (6.30; 2.35-
16.88) than infants with non-atopic eczema, even after
excluding infants with early wheeze. The authors also
found that the strongest association between eczema
and asthma were for eczema that started in the first 6
months of life and was severe, particularly in boys. In
short, these findings were consistent with the atopic
march and at odds with the interpretation of Illi et
al..11 Perhaps, the lack of assessment of the temporal
sequence of eczema, sensitization and wheeze, and
the lack of stratification by sex in the German data
led to the questionable conclusion that the atopic
march was not a real phenomenon.
Another study analyzed the relationship between
childhood eczema and asthma over time using data
from the Tasmanian Longitudinal Health Study26: this
was the first study to investigate the influence of ec-
zema on the development of asthma from childhood
to middle-age. Burgess et al. found that childhood ec-
zema was significantly associated with new-onset
asthma in three separate life stages: pre-adolescence
(hazard ratio 1.70; 95% CI 1.05-2.75), adolescence
(2.14; 1.33-3.46), and adult life (1.63; 1.28-2.09) as well
as over the life span from the ages of 8 to 44 years
(1.73; 1.42-2.12). These results provide strong evi-
dence supporting the view that the atopic march con-
tinues well past childhood. Thus the weight of evi-
dence now favors the atopic march as being a real
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phenomenon, particularly in boys. Evidence for im-
paired skin-barrier function in eczema, together with
recent developments in eczema genetics, strengthens
the argument favoring a progressive atopic march.
AD causes physical and emotional distress for pa-
tients and their families. The impact is greater than
with psoriasis and is equivalent to other serious medi-
cal conditions such as early onset of diabetes melli-
tus.27 AD can have a profound impact on the quality
of life of pediatric patients.28-31 Children with AD are
adversely affected in terms of disrupted sleep, school
performance, social activities, and participation in
sports28,29 and may suffer embarrassment, peer rejec-
tion, teasing, and bullying.29 Parents report loss of
sleep, stress, and loss of leisure time30; families can
become socially isolated by avoiding interactions with
relatives and friends to minimize awkward situ-
ations,31 and overprotection of a child with AD can
provoke feelings of jealousy in spouses and siblings.32
In AD patients evaluated by polysomnography, ac-
tigraphy, TNF, IL-6, and IL-10 a positive correlation
between increase of AD severity and itching and in-
crease of IL-6 and reduced quality of sleep was
found.33
A recent study prospectively investigated the rela-
tionship between infant eczema (within first 2 years
of age), infant sleeping problems (within first 2 years
of age), and the risk of mental health problems at 10
years of age. A population-based birth cohort was re-
cruited in Germany and the subjects were followed
until 10 years of age. Physician-diagnosed eczema,
parent-reported sleeping problems, and known envi-
ronmental risk factors for atopy were regularly as-
sessed until 10 years of age. Mental health was meas-
ured using the Strenghts and Difficulties Question-
naire (parent version) at 10 years of age. In the fully
adjusted model, children with infant eczema were at
increased risk of hyperactivityinattention at 10 years
of age (odds ratio 1.78; 95% CI 1.02-3.09). Infant ec-
zema with concurrent sleeping problems predicted
emotional problems (OR 2.63; 95%CI 1.20-5.76) and
conduct problem (OR 3.03; 95%CI 1.01-9.12) at 10
years of age. Infant eczema with concurrent sleeping
problems appears to be a risk factor for the develop-
ment of mental health problems.34 Patients with
chronic relapsing AD often suffer from stress-related
exacerbations, exhaustion, depression, anxiety and
helplessness. They may feel to be unable to influence
the course of their disease, and often develop prob-
lems in social interaction. These case reports focus
on the different possibilities in addition to classical
dermatologic therapy-empathic psychosomatic-orie-
ntated conversations, strategies of behavioural medi-
cine and the effect of long-term psychodynamic psy-
chotherapy.35
PATHOPHYSIOLOGY OF AD
AD originates from a late, T-cell mediated reaction as-
sociated to the formation and production of memory
T-cell of Th2 type, occurrence of homing receptor at
skin level and CLA antigens.36 Extrinsic or allergic
AD shows high total serum IgE levels and the pres-
ence of specific IgE for environmental and food aller-
gens, whereas intrinsic or non-allergic AD exhibits
normal total IgE values and the absence of specific
IgE. While extrinsic AD is the classical type with high
prevalence, the incidence of intrinsic AD is approxi-
mately 20% with female predominance. The clinical
features of intrinsic AD include relative late onset,
milder severity, and Dennie-Morgan folds, but no ich-
thyosis vulgaris or palmar hyperlinearity. The skin
barrier is perturbed in the extrinsic, but not intrinsic
type. Filaggrin gene mutations are not a feature of in-
trinsic AD. The intrinsic type is immunologically
characterized by the lower expression of interleukin
(IL)-4, IL-5, and IL-13, and the higher expression of
interferon-gamma. It is suggested that intrinsic AD
patients are not sensitized to protein allergens, which
induce Th2 responses, but with other antigens, and
metals might be one of the candidates of such anti-
gens.37
To understand the pathophysiology of AD requires
careful consideration of the role of skin: an intact epi-
dermal compartment is a prerequisite for the skin to
function as a physical and chemical barrier.38 The
skin of atopic dermatitis patients is “dry” and “rough”,
suggesting disruption of epidermal barrier function.
Ichthyosis vulgaris is characterized by dry and rough
skin with fish-like scales and has been known to be
frequently accompanied by AD.39
The role of a genetically-impaired epidermal bar-
rier as the primary cause of the rapid increase in
prevalence of AD and respiratory atopy is important,
based on available clinical and experimental data. The
subsequently increased exposure to irritants and al-
lergen post-natally in predisposed individuals would
lead in a subset of these to a specific TH2 cell activa-
tion favouring the development of IgE responses to
allergens. Other routes of sensitization are probably
significant, but skin offers a good target to implement
prevention strategies, so far completely ignored in
the prophylactic recommendations given to high-risk
families. Candidate genes for skin-barrier impairment
are possibly those associated with ichthyosis vulgaris
and X-linked hypohidrotic ectodermal dysplasia.40
Also pivotal is the role of Langherans cells. Skin erup-
tion in AD occurs mainly in the epidermis, whose bar-
rier function and cytokine expression have been re-
vealed to be abnormal. In fact, the epidermis contains
Langerhans cells, a type of antigen-presenting cells,
which could be considered the sentinel of the im-
mune system. Some AD patients were found to have
mutations or SNPs (single-nucleotide polymor-
phisms) in the filaggrin gene, which affect the epider-
mal barrier function. Proteinases in the epidermis are
of importance in maintaining the epidermal barrier,
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and their abnormalities have been reported in AD.
Defects of various cytokines and chemokines pro-
duced by keratinocytes have also been reported. Thy-
mic stromal lymphopoietin (TSLP) produced by
keratinocytes has recently been a focus in AD. Adren-
ergiccholinergic responses in the epidermis could
also influence the pathogenesis of AD. Considering
epidermal keratinocytes as a trigger of immune ab-
normalities, and not only as a peripheral effector,
would be important to further disclose the pathogene-
sis of this enigmatic disorder.41 This highlights how
in clinical practice the role of skin is fundamental in
understanding the atopy status: in fact, the first mani-
festations of atopy take place in the skin, with particu-
lar importance for the transepidermal water loss
(TEWL) and the decrease of ceramides. Gupta et al.
stated that “Skin barrier function as assessed by
TEWL is intrinsically compromised in children with
AD but not in children with other allergic conditions.
The magnitude of skin barrier dysfunction correlates
with AD disease severity”.42 Of interest, over the past
few years, skin barrier dysfunction has emerged as a
critical driving force in the development and progres-
sion of AD.43 The barrier function depends upon the
horny layers (stratum corneum), obtained by the dif-
ferentiation of keratinocytes and composed by cross-
linked proteins including filaggrin (FLG), which is
produced by pro-filaggrins by the enzyme capsase-14.
FGL is a protein contained in the granular layer of
the epidermidis that plays an important role in the ag-
gregation of keratin filaments to form a rigid mar-
ginal band in stratum corneum, the indispensable
stage in keratinocyte terminal differentiation.44 Muta-
tion in the filaggrin gene causes decreased barrier
function of the horny layers of the epidermidis.45 The
expression level of filaggrin has been known to be de-
creased in atopic dermatitis patients at both the pro-
tein and mRNA levels.46 To the integrity of skin bar-
rier cooperate sphyngosines and ceramides, that are
lipids scarcely present in the eczematous skin. Re-
duced levels of ceramides cause and increase TEWL,
dry skin and fissuration with enhanced passage of an-
tigens through the skin.47 Identification of loss-of-
function mutations in the gene encoding epidermal
structural protein filaggrin as a major risk factor for
AD has shed new light on disease mechanism in
AD.48 It has been widely replicated that FLG gene
mutations are associated with more severe AD, early
onset of the disease, enhanced systemic allergen sen-
sitization, and an increased risk of asthma in patients
with a previous history of eczema.49,50 The critical
link between abnormal skin barrier in FLG-deficient
patients with AD and Th2 polarization might be ex-
plained in part by enhanced allergen penetration
through the skin accompanied by increased produc-
tion of TLSP. Insults from allergens or microbes can
trigger keratinocytes to produce TLSP, an IL-7-like
cytokine that is overexpressed in epidermidis of pa-
tients with AD, and signal immature myeloid den-
dritic cells to induce development of Th2 cells by in-
ducing upregulation of OX40 ligand in the absence of
IL-12 production.51
This interaction, in which dendritic cells seem to
play a pivotal role,52 leads to a cell response in the
skin initially of T helper type 2 (Th2) but later of Th1,
and a systemic Th2 response inducing the isotype
switching to IgE synthesis and the involvement of
eosinophils.53,54
When Th2 cells are activated, the production of a
proinflammatory cytokines and chemokines pattern
sustains the persistence of inflammation. Known AD-
related cytokines are IL-5, IL-13 and tumor necrosis
factor (TNF)-α, with emerging importance for IL-17,
which seems to drive airway inflammation following
cutaneous exposure to antigens,55 and IL-31, which is
expressed primarily in skin-homing Th2 cells.56 Skin-
homing is another crucial event in AD, mediated by
the cutaneous lymphocyte-associated antigens (CLA)
receptor, which characterizes T cell subpopulations
with different roles in AD and asthma.
The epidermis is not only a physical barrier, but
also functions as a chemical and immunological bar-
rier, producing various cytokines and antimicrobial
peptides. In AD patients, cathelicidine (LL37) and β-
defensin (HBD-2), antimicrobial peptides, are de-
creased, which is considered to be the cause of fre-
quent skin infections by Staphylococcus and Strepto-
coccus.57 The altered skin structure and a deficiency
in antimicrobial peptides favour colonization, in par-
ticular yeast colonization (especiallyMalassezia spp.).
Sensitization to the yeast occurs almost exclusively in
AD patients. S. aureus enterotoxins with superanti-
genic activity stimulate activation of T cells and
macrophages. So far, AD skin lesions are orches-
trated by the local tissue expression of proinflamma-
tory cytokines and chemokines with activation of T
lymphocytes, dendritic cells, macrophages, keratino-
cytes, mast cells, and eosinophils which lead to the
skin inflammatory responses.58
THE CAUSES OF AD
THE ROLE OF FOODS
AD is characterized by elevated levels of serum IgE
and sensitization to environmental allergens includ-
ing foods, indoor inhalants, and outdoor inhalants.59
Epidemiological studies have shown a progression of
atopic sensitization from food allergens to inhalant al-
lergens. The German MAS (cited above), which
prospectively followed 1314 infants >10 years, demon-
strated that approximately 10% of infants were sensi-
tized to food allergens at 1 year of age; however, aller-
gic reactions to food were seen in 8% of children. By
age 6, only 3% of children were sensitized to food al-
lergens. Conversely, 1.5% of infants were sensitized to
inhalant allergens at 1 year; at 5 years, 30% of chil-
dren were sensitized to inhalant allergens.60 This
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study also demonstrated that the combination of AD,
atopic family history, and food sensitivity is highly
predictive of future respiratory allergy and asthma.61
AD and food allergy (FA) frequently herald the aller-
gic march. They commonly co-exist with severe and
persistent AD, particularly in those with early onset.62
FA is emerging as a major clinical and public health
problem worldwide. It affects approximately 5-8% of
children - with greatest prevalence in the first few
years of life and gradual decrease during the first dec-
ade as tolerance develops - and 1-5% of adults. Such
prevalence has risen substantially over the past dec-
ade, in parallel to the rise in prevalence previously
seen for other atopic conditions.63-66 Despite this, our
current understanding on the etiology and biological
mechanisms of FA is still incomplete. It is generally
believed that FA, like the other allergic diseases such
as asthma and AD, is determined by both environ-
mental and genetic factors.67-69
Five foods - eggs, milk, soy, peanut, and wheat - are
responsible for the highest percentage, 90%, of reac-
tions in young children.67 Obviously, the natural
course of FA is different for each allergen. Allergies
to peanuts, nuts, and seafood are more likely to per-
sist, with a small fraction of patients developing toler-
ance, whereas allergies to milk, eggs, wheat, and soy
generally disappear by late childhood.68
Foods as a trigger of AD have long been a subject
of debate.70-72 The first documented description of
food allergy as a cause of AD dates back to 1915,
when Scholoss reported an eczematous rash caused
by foods which improved after their elimination from
the diet.73 Currently, foods are believed one of the
most common cause of AD, but the association be-
tween foods and AD is stark. Though sensitization to
foods frequently occurs in children and is more
prevalent in children with AD, its causative role in the
disease is often not as significant as often believed.74
As a matter of fact, contrasting results in previous
studies on the role of foods in pathogenesis of AD in
children were reported. Some authors stated that
foods often deteriorate skin lesions in children with
AD,75-77 but others report that foods are not usually
involved in exacerbations of the disease in children
with AD.78,79 It is important to note that patients with
AD often show unpredictable, irregular aggravation
of skin lesions.80 In the current practice, more than
90% of parents and more than 60% of physicians spot
in food allergy the culprit of DA and this leads to an
excess of allergy specialist consultation and allergy
testing.81 Indeed, the role of diet both as cause and
management of AD is controversial, with pediatri-
cians and allergists in favour and dermatologists con-
trary.82 On one hand, it is clear that foods may di-
rectly provoke flares of AD in sensitized infants,83 on
the other hand, true food-induced AD is rare.84 Such
opposite points of view can cause confusion in par-
ents and lead to elimination diets without appropriate
guide by a nutritionist. Certainly, also for AD “it can
be argued that the earlier interventions can be made,
the greater the effect may be on the disease”.85 The
relationship between food and AD is complex. A com-
mon misunderstanding is that food allergies have a
significant impact on the course of AD, resulting in
uncontrolled attempts at elimination diets and under-
treatment of the skin itself.86 Surely, to better under-
stand the cutaneous reactions induced by FA it is im-
portant to recognize that just as AD can be associated
with or without elevated immunoglobulin E (IgE) lev-
els, FA can also be IgE or non-IgE mediated.63 In-
deed, the overestimation of the effect of FA on AD
most probably stems from the observation of more
common, immediate-type, IgE-mediated skin reac-
tions, such as urticaria and erythema. These reac-
tions are more visible and readily attributable to food
exposure because of their rapid development, but
they do not represent flares of AD. By contrast, ec-
zematous flares that occur as delayed-type hypersen-
sitivity reactions are generally non-IgE-mediated.
These reactions may be overlooked because they de-
velop 2 or more hours after food challenges, and this
delay may render the correlation between the food
exposure and reaction more difficult.83
It is of the utmost importance to avoid the many
mistakes of the past, such as dietetic interventions
during pregnancy,87-89 to reach correct diagnosis.
Moreover, restricted diets may even be potentially
harmful for the fetus, with a significantly lower mater-
nal weight gain during pregnancy and a non signifi-
cant reduction in weight at birth and an increased
risk of preterm birth.90 Studies with follow-up beyond
age 1 to 2 years have found a poor influence of prena-
tal diet on infants with AD, and the critical revision of
elimination diets in the mother during pregnancy or
lactation did not draw to any conclusions on their pos-
sible effect in preventing or improving AD or other
atopic disorders.90
It is apparent that the study of AD caused by true
FA is confusing and controversial. It is often difficult
to conclusively prove that specific foods induce der-
matitis because clinical cases do not correlate well
with skin prick test (SPT) and specific IgE measure-
ment in serum.74 Before one solicits tests to evaluate
FA, the distinction between sensitization and allergy
needs to be recognized. The presence of food-specific
IgEs supports sensitization, but it does not necessar-
ily translate to FA, which is a clinical response upon
exposure to a specific food. Children who are sensi-
tized may not necessarily develop a clinical reaction.
For example, a child who has developed tolerance to
cow’s milk may have persistent milk-specific IgE but
may be able to ingest cow’s milk without any clinical
symptoms.86 The first suspicion for FA usually arises
from patients. Unless major immediate anaphylactic
reactions have occurred, however, history has proven
to be an unreliable way to diagnose FA.91 A number
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of studies have reported poor correlation, with only
25% to 48% sensitivity and 72% to 97% specific-
ity.63,77,92-94 Many of the symptoms of FA are IgE-
mediated, and therefore initial testing in an outpatient
setting is determined on the basis of the presence of
food-specific IgEs. The SPT has a high negative pre-
dictive value (>95%) and is most informative when it
is negative. However the positive predictive value
ranges between 30% and 50%.93 Therefore, the SPT is
useful for excluding immediate food hypersensitivity,
but a positive result may only suggest such hypersen-
sitivity.63,91,95 Laboratory testing for food-specific IgE
also has a high negative predictive value, estimated to
be 75%, but the positive predictive value if often low,
ranging from 20% to 60%.83,94 Recently, diagnostic lev-
els of food-specific IgEs have been determined, and
specific IgEs above these levels may offer a positive
predictive value of >95% for FA. These levels are avail-
able for certain foods, most reliably for hen’s egg,
cow’s milk, fish, and peanut, and they are applicable
to young children younger than 2 years of age.95
However, the decision points are not reliable for
wheat and soy.95 Furthermore, the clinician must pay
attention to the type of assay used because the actual
diagnostic levels may differ as a result of technical
discrepancies and differences in allergen sources
among the different assays. Finally, these decision
points are for immediate-type reactions and are not
meant to predict risk for late eczematous reactions to
foods.96 Although SPT and serum IgE measurements
can confirm sensitization, it can not prove clinical al-
lergy to a specific food on its own with reliability. The
diagnostic levels for specific IgE can help to avoid
oral food challenges (OFCs), but the utility of this
tests is limited for certain foods in young children, as
long as the assay used is the same as that in pub-
lished studies. The “gold standard” test to confirm or
disprove food allergy is the oral food challenge
(OFC), particularly in the form of double-blind,
placebo-controlled OFCs.63,97 OFCs are time-
consuming and potentially able to elicit severe reac-
tions, and they should be performed by experienced
health-care professionals who have access to emer-
gency equipment. Despite the mentioned caveats,
OFCs are especially useful because observation after
food exposure for 24 hours or more can allow both
IgE and non-IgE-mediated processes to be as-
sessed.98 Eczematous allergic reactions to foods have
similarities to allergic contact dermatitis in that both
are T-lymphocyte mediated, with the former being as-
sociated with food-specific T-lymphocytes.99 In addi-
tion, their clinical morphologies resemble each other.
These shared features have led to the introduction of
the atopy patch test (APT) as a way of investigating
food-induced eczema. APT is carried out in a similar
fashion to patch tests performed in dermatology clin-
ics, by the application of small amounts of food aller-
gens to a clear area on the patient’s back. The applica-
tion sites are checked for contact urticaria at 20 min-
utes and again at 48 and 72 hours.100 There are re-
ports supporting the use of APT in combination with
IgE testing to increase the positive predictive value
for diagnosing FA, thereby bypassing the need for
OFCs.74 However, the authors of other prospective
studies have reported that APT offers only a small
added benefit, if any, to standard SPT and serum IgE
measurements.101 Furthermore, the methodology ap-
pears to require more standardization and therefore
in not yet generally recommended for routine diagno-
sis of food-induced AD.102
THE ROLE OF HOUSE DUST MITES
Recent research highlighted the important role
played by house dust mites (HDM) as a cause of AD.
Since 1967, HDM have been shown to be the main al-
lergens blamed for household dust allergy103 and are
currently recognized worldwide as a major cause of
allergic diseases.104 The most frequently responsible
mites are Dermatophagoides pteronyssinus and Derma-
tophagoides farinae (belonging to the family Pyro-
glyphidae) which produce a wide array of allergens
occurring in mite bodies and faeces. Currently, there
are 22 defined mite allergens, some of them acting as
major allergens based on the recognition by IgE from
more than 50% of mite allergic patients.105 Most of
these allergens are proteolytic enzymes. It is appar-
ent that the allergens most clinically important are
Der p 1 and Der p 2 from D. Pteronyssinus and Der f 1
and Der f 2 from D. farinae. The group 1 allergens
are cysteine protease and the group 2 allergens show
structural homology with MD-2, a co-receptor of the
Toll-like receptor whose ligand are lipopolysaccha-
rides (LPS).105
The importance of dust mites in AD is suggested
by their detection on the skin, clothes, and bedding
of patients with AD106,107 but especially by the in-
creasing knowledge being compiled regarding the
ability of airborne allergens to go through the skin.
As reported above, patients with AD have a
baseline-impaired barrier function that allows pro-
teins to enter into the viable epidermis.42,43 In AD, air-
borne proteins have the ability to penetrate into the
epidermis and worsen AD severity through 3 mecha-
nisms: inherent proteolytic enzyme activity, activation
of proteinase-activated receptors-2 (PAR-2), and im-
munoglobulin E (IgE) binding, that leads to inflam-
mation.
Concerning the first mechanism, airborne proteins
produced by HDM, but also by cockroaches, have di-
rect proteolytic activity on the skin that contribute to
barrier impairment and delayed barrier recovery in
patients with AD.108,109 Such proteins have been ex-
tensively investigated and consist primarily of cyste-
ine and serine proteases,108-110 which may directly
disrupt epithelial tight junctions, induce degranula-
tion of eosinophils, and activate keratinocytes, caus-
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ing increased production of interleukin (IL)-6, IL-8,
and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF).110-112 These effects contribute to bar-
rier impairment and induce local inflammation. In ad-
dition, the exogenous proteases alter the skin’s natu-
ral equilibrium between endogenous proteases and
endogenous protease inhibitors causing a delayed
barrier recovery in the stratum corneum.113,114 The al-
tered barrier function allows not only easier access
into the epidermis for airborne proteins, but also for
microbes and irritants. When they have breached this
barrier they can easily interact with local immune
cells to initiate the Type-I-immediate and Type-IV-
delayed hypersensitivity reactions common among
patients with AD.108,115 It was also shown that apply-
ing certain weed pollens, animal dander, and moulds
onto asymptomatic skin caused an eczematous reac-
tion in a subgroup of patients with AD.112 However,
the specific proteases associated with weed pollens,
animal dander, and moulds are not as well described
as those from dust mites.
The second mechanism through which airborne
proteins may exacerbate AD is the direct activation of
the PAR-2 receptor on epidermal keratinocytes and
dermal unmyelinated nerve fibres. The PAR-2 recep-
tor is crucial to neural transmission of the itch sensa-
tion, maintenance of the epidermal calcium ion gradi-
ent, and barrier recovery, although the exact mecha-
nisms of action are not completely clear.108,116 Biop-
sies from skin of AD patients characteristically show
an increased density of PAR-2 receptors.116 Proteins
of HDM, as well as of cockroach, have been shown to
activate PAR-2 receptors.110 The PAR-2 receptor is
also an increased nuclear factor kappa-light-chain en-
hancer of activated B cells (NF-kB) and increased
production of leukotriene B4 and prostaglandin
E2.108,117 Therefore, chronic activation of PAR-2 re-
ceptors induces epidermal barrier dysfunction,
chronic itch, and delayed skin barrier recovery.
The third mechanism is the classic IgE-mediated
allergy. Airborne proteins bind to specific IgE anti-
bodies and elicit the release of histamine and other
inflammatory mediators from mast cells and baso-
phils, which result in tissue damage.118,119 In addi-
tion, IgE-mediated histamine release from mast cells
exacerbates the itch-scratch cycle, which can further
aggravate AD.112 The skin of AD patients shows in-
creased numbers of Langerhans cells expressing the
high-affinity IgE receptor FcεRI compared with the
skin of patients without AD.118 Moreover, it was re-
ported that skin biopsies taken from patients with AD
while APT was being performed, have increased che-
motactic signals and invasion of dendritic epidermal
cells within 24 to 48 hours after protein application.120
Nonetheless, the incomplete effectiveness of antihis-
tamines in relieving AD-related itching suggests that
other mechanisms at the same time at work, such as
the proteolytic effects and the PAR-2 binding cited
above.
The role played by the cytokine TNF-α is clearly
apparent through its capacity to regulate the expres-
sion of TSLP in keratinocytes.121,122 Of interest, the
overexpression of TSLP seems sufficient to drive the
progression from AD to asthma, that is, the atopic
march.123 At the same time the role of Toll-like recep-
tors (TLRs) is currently under investigation. As re-
ported above, the co-receptor MD-2 of TLR has as
ligand the LPS. Recent studies have shown that
keratinocytes express TLRs 1-6 and 9, and that they
respond to LPS through the production of a number
of cytokines and chemokines.124-126
Other mechanisms possibly involved in the trigger-
ing of AD by dust mites are the ability to activate hu-
man dermal endothelial to express adhesion mole-
cules and to secrete particular cytokines, and the acti-
vation of inflammasome. As far as the first aspect is
concerned, mite extracts stimulated endothelial cells
to express intercellular adhesion molecule-1 (ICAM-
1), vascular cell adhesion molecule-1 (VCAM-1), and
E-selectin and to secrete interleukin (IL)-6, IL-8,
monocyte chemoattractant protein (MCP-1), and
granulocytemacrophage colony stimulating factor
(GM-CSF). By contrast, D. farinae or D. pteronyssinus
extracts depleted of endotoxin activity expressed only
constitutive levels of ICAM-1, VCAM-1, and E-
selectin.127 Taking into account the inflammasome ac-
tivation, D pteronyssinus activated caspase-1 and in-
duced caspase-1-dependent release of IL-1β and IL-18
from keratinocytes, and stimulated assembly of the
inflammasome by recruiting apoptosis-associated
specklike protein containing a caspase-recruitment
domain (ASC), caspase-1, and nucleotide-binding oli-
gomerization domain, leucine-rich repeat and pyrin-
domain containing 3 (NLRP3) to the perinuclear re-
gion. Activation of the NLRP3 inflammasome by D.
pteronyssinus was dependent on cysteine protease ac-
tivity, leading the authors to suggest that dust mite al-
lergens are danger signals for the skin and may play
a pivotal role in the pathogenesis of AD.128
The knowledge of the mechanisms underlying the
kind of sensitization and the type of clinical expres-
sion is far from exhaustive. It was long believed that
the load of mite allergens which a subject is exposed
to could be an essential factor in determining simple
sensitization or clinical allergy. However, recent data
have indicated that this relationship is not linear, as
the highest exposure to dust mites was not directly
associated with the risk of allergic outcome.129 In-
stead, the mite species seem to have an influence on
the type of allergy which subjects develop. In a large
group of around 1,700 children, respiratory allergy
was associated with both D. pteronyssinus and D. fari-
nae exposure, while only the latter was associated
with AD.130 In a recent study, children with asthma
and AD showed different sensitization profiles to
HDM, with a sensitization pattern more extensive
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and significantly higher IgE levels for Der p 1 and
Der p 5 in the AD group.131
As far as allergy testing is concerned, the SPT or
the measurement of specific IgE antibodies to HDM
in serum is used to indicate sensitization, but they
must be combined with the subject’s case history to
diagnose clinical allergy. The SPT and specific IgE
strictly assess type-I IgE mediated allergic responses
to a protein, without assessing the ability of the pro-
tein to induce inflammation. Patients with AD com-
monly show sensitization to a number of allergens,
which increases with the severity of the disease.132 In
a cohort of 94 children with AD followed up from in-
fancy to 7 years of age, 80% of the children became
sensitized to aeroallergens and 75% of them noticed
symptoms when exposed.133 It seems conceivable
that this phenomenon may be related to the mecha-
nisms of skin barrier disruption, mucosal absorption
of allergens, and consequent local inflammation de-
scribed above. Among aeroallergens, HDM seems to
play a major role.134-136 However, the SPT has high
sensitivity because of the high prevalence of sensiti-
zations but it is nonspecific in distinguishing aero-
allergen driven AD when compared to patient history.
In fact, sensitivity for aeroallergens is comprised be-
tween 68% and 100% while specificity ranges between
33% and 71%. Thus, SPT is likely to detect a secon-
dary phenomenon to the physiology of AD and is not
a reliable marker to identify patients with
aeroallergen-driven AD.137
The measurement of specific IgE level in serum
has similar characteristics, regarding the linear asso-
ciation between increasing severity of AD and in-
creasing levels of specific IgE to HDM and other
aeroallergens,138 the fact that patients with AD show
higher HDM-specific IgE levels than patients with
asthma,139 and the diagnostic performance showing
high sensitivity (65% to 92%) but low specificity (33%
to 69%).137 Instead, the APT assesses type-IV delayed
hypersensitivity responses to a protein and was intro-
duced in 1989 by Ring et al. as a tool to investigate
the role of aeroallergens in atopic dermatitis.140 Dif-
ferently from SPT, the APT essentially assesses the
patient’s inflammatory response to a given protein.
Such inflammation is thought to be primarily due to a
delayed hypersensitivity reaction, but there are data
suggesting that the direct proteolytic activity of the
protein or binding of PAR-2 receptor may be relevant
as well.141
It has been reported that patients with an air-
exposed pattern of AD have significantly higher rates
of positive APT results when compared to patients
with non air-exposed skin areas.142 The APT shows a
clear advantage over the SPT in terms of specificity,
which ranges between 65% and 95%.137,143 Factors in-
fluencing the results include patient selection by AD
severity and distribution, use of skin abrasion in test-
ing methodology, type of protein, and concentration
of protein.137
Indeed, there is notable evidence supporting the
capacity of the APT to reproduce the pathophysi-
ologic events of AD. In biopsy-based studies, a Th2
cytokine pattern was found 24 hours after APT, but a
shift to a Th1 pattern, as occurs in chronic AD skin le-
sions, was noted after 48 hours.144,145 A more fre-
quent positivity to APT was reported in patients with
allergen-specific lymphocyte proliferation and expres-
sion of activation markers on peripheral blood T-cells
following in vitro stimulation with house dust mite,
cat or grass pollen allergens, than in patients without
lymphocyte proliferation.146 Application of the APT to
skin of subjects with AD was followed by an influx of
inflammatory dendritic epidermal cells.147 A signifi-
cant increase of TEWL was reported in the site of
APT application, both after 48 and 72 hours, com-
pared with the control skin site.148 By immunohisto-
chemical analysis, the presence of IgE on Langer-
hans cells was demonstrated in positive APT reac-
tions to Dermatophagoides in patients with mite-
associated AD.149 Clinically, patients with a diagnosis
of intrinsic AD because of negative IgE tests actually
had a positive APT for dust mites.150 This aspect is of
particular interest, because AD patients with negative
SPT and IgE measurement in serum should be de-
fined as nonatopic unless APT is performed. A num-
ber of studies evaluated how common such patients
are, with different observations. In one study the rate
of positive APT in nonatopic patients was 23%,151
while in another study comparing AD patients with
extrinsic and intrinsic forms, the rate of positive APT
was 47.4% and 66.6%, respectively.152 In a European
multicenter study, which included 314 patients with
AD, the frequency of clear-cut positive APT reactions
ranged from 39% with dust mites to 9% with celery. A
remarkable observation from the study was that posi-
tive APT in face of all SPT and sIgE testing negative
was found in 7% of the patients, whereas a positive
APT without SPT or sIgE for the respective allergen
was seen in 17% of the patients.153 This lead the
authors to conclude that, as no gold standard for
aeroallergen provocation in AD is available, the rele-
vance of aeroallergens for AD might be evaluated by
APT in addition to SPT and specific IgE measure-
ment. New observations increased the value of the
APT. In children with respiratory symptoms an exclu-
sive positivity to APT with dust mites was observed154
and another study reported that in 63 children with
mite-induced asthma and rhinitis, all with positive
SPT and specific IgE in serum, 16 (25%) were positive
to mite APT too, indicating that delayed hypersensi-
tivity reactions were involved.155
These observations lead us to investigate the possi-
ble factors underlying the positive result of APT in
subjects with respiratory symptoms. In our first
study, conducted on 297 children, we could demon-
strate that in subjects with asthma or rhinitis a posi-
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tive APT to dust mite was strongly associated with
the presence of current or past AD.156 Most subjects
with respiratory disease but a negative history for
AEDS had a positive SPT. Multivariate analysis
showed that there was an increased likelihood of a
positive APT result in patients with AD (odds ratio
17.4), in patients with AD and respiratory disease
(odds ratio 21.9), and in patients with past AD and
respiratory disease (odds ratio 22.8). These findings
were confirmed in a study on a large population of
465 children aged 0.4 to 17.6 years. They were di-
vided into four groups: group A, current AD (40 pa-
tients); group B, current AD with respiratory symp-
toms (156 patients); group C, past AD with respira-
tory symptoms (203 patients); and the control group,
respiratory symptoms with no history of AD (66 pa-
tients). The APT was significantly more frequently
positive in groups with current AD (groups A and B)
or past AD (group C) than in the control group, while
SPT and specific IgE in serum were significantly
more frequently positive in the control group.157 Such
significant differences in response to APT in patients
with diverse clinical expressions suggest that distinc-
tive immunologic mechanisms underlie the different
manifestations of hypersensitivity to dust mites. It
seems conceivable that in subjects with a negative
history for AD sensitization occurs by respiratory
route and leads to the development of a Th2 pattern
of response with ongoing production of specific IgE
and consequent positive SPT and in vitro IgE tests.
By contrast, in cases where the mite allergens enter
through the skin, as can occur during exposure to
common indoor concentrations of the major allergen
Der p 1,158 such entering being facilitated by its pro-
teolytic activity and in the presence of a filaggrin-
dependent skin barrier dysfunction, a different chain
of events is likely to take place. This is ultimately re-
vealed by positive APT and negative SPT and in vitro
IgE tests.
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